We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App

HPV Self-Collection Solution Improves Access to Cervical Cancer Testing

By LabMedica International staff writers
Posted on 17 May 2024
Print article
Image: Roche Cell Collection Medium provides long-term stability for specimens collected via self-collection (Photo courtesy of Roche)
Image: Roche Cell Collection Medium provides long-term stability for specimens collected via self-collection (Photo courtesy of Roche)

Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV). A staggering 90% of these deaths occur in low- and middle-income countries. Screening for HPV is crucial as it helps identify women at risk of developing cervical cancer, thereby enabling early intervention before the cancer can develop. In regions where healthcare resources are scarce, enhancing the accessibility of screening and reducing obstacles to sample collection are critical to preventing this disease. Now, a novel HPV self-sampling method expands the availability of cervical cancer screening by allowing patients to collect their samples privately while at a healthcare facility.

Roche (Basel, Switzerland) has received FDA approval for its HPV self-collection solution, one of the first available in the United States where more than half of the women diagnosed with cervical cancer have either never been screened or do so infrequently, often missing out on routine screening opportunities. Several factors deter individuals from participating in cervical cancer screening programs, including limited access to healthcare, social and economic barriers, past traumatic experiences, cultural concerns, and feelings of embarrassment.

Roche’s HPV self-collection solution addresses these barriers by providing an alternative to traditional clinician-collected procedures, while still offering accurate and dependable results that allow healthcare professionals to make informed decisions regarding patient care. The self-collection method facilitates accessible screening, where individuals can take their own vaginal samples in a healthcare setting. These samples are then analyzed using Roche’s cobas molecular instrument in a laboratory. Individuals who test positive for HPV would subsequently seek further care from healthcare providers.

“With vaccinations, innovative diagnostic tools and screening programs, achieving the WHO’s goal of eliminating cervical cancer by 2030 is within reach,” said Matt Sause, CEO of Roche Diagnostics. “Our HPV self-collection solution helps support this goal by reducing barriers and providing access to HPV screening by allowing people to privately collect their own sample for HPV testing.”

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.